Ginel Pedro J, Sileo Maria T, Blanco Beatriz, Garfia Bartolomé, Quintavalla Fausto
Department of Animal Medicine and Surgery, Faculty of Veterinary Medicine, University of Córdoba, Spain.
Am J Vet Res. 2012 Feb;73(2):237-41. doi: 10.2460/ajvr.73.2.237.
To compare the adrenocortical response of healthy dogs to a commonly used dose of a nonadsorbed tetracosactide product (tetracosactide) with responses to 2 doses of a depot formulation of tetracosactide (depot tetracosactide).
14 dogs.
Dogs were randomly assigned to receive tetracosactide (5 mg/kg, IV) or depot tetracosactide (250 μg, IM, or 5 μg/kg, IM). Dogs received each treatment once with a 2-week interval between treatments. Blood samples were assayed for cortisol, progesterone, 17-hydroxyprogesterone, androstenedione, and estradiol concentrations.
Serum cortisol concentrations were significantly higher than the preadministration (baseline) concentrations for all treatments 60 minutes after administration of ACTH. Peak cortisol concentration was detected 180 minutes after IM administration of 250 μg of the depot tetracosactide. Serum concentrations of progesterone, 17-hydroxyprogesterone, and androstenedione did not differ significantly from baseline concentrations after stimulation with the 5 μg/kg dose of depot tetracosactide. Adrenal gland progesterone response was significantly higher than baseline concentrations at 60 minutes after administration of the 250-μg dose of depot tetracosactide, and the 17-hydroxyprogesterone and androstenedione responses were significantly higher than baseline concentrations at 120 minutes. Compared with the response to tetracosactide, adrenocortical response was higher and more sustained following administration of the depot tetracosactide, except for androstenedione concentration, which had a nonsignificant response.
Except for androstenedione concentrations, a high dose of the depot tetracosactide (250 μg, IM) induced an adrenocortical response similar to that after administration of tetracosactide. Thus, depot tetracosactide may represent an alternative to the nonadsorbed tetracosactide product.
比较健康犬对常用剂量的非吸附性二十四肽促皮质素产品（二十四肽促皮质素）的肾上腺皮质反应与对两种剂量的长效二十四肽促皮质素制剂（长效二十四肽促皮质素）的反应。
14只犬。
犬被随机分配接受二十四肽促皮质素（5毫克/千克，静脉注射）或长效二十四肽促皮质素（250微克，肌肉注射，或5微克/千克，肌肉注射）。犬每种治疗接受一次，治疗间隔为2周。检测血样中的皮质醇、孕酮、17-羟孕酮、雄烯二酮和雌二醇浓度。
给予促肾上腺皮质激素（ACTH）后60分钟，所有治疗的血清皮质醇浓度均显著高于给药前（基线）浓度。肌肉注射250微克长效二十四肽促皮质素后180分钟检测到皮质醇浓度峰值。用5微克/千克剂量的长效二十四肽促皮质素刺激后，血清孕酮、17-羟孕酮和雄烯二酮浓度与基线浓度无显著差异。给予250微克剂量的长效二十四肽促皮质素后60分钟，肾上腺孕酮反应显著高于基线浓度，17-羟孕酮和雄烯二酮反应在120分钟时显著高于基线浓度。与对二十四肽促皮质素的反应相比，给予长效二十四肽促皮质素后肾上腺皮质反应更高且更持久，但雄烯二酮浓度反应不显著。
除雄烯二酮浓度外，高剂量的长效二十四肽促皮质素（250微克，肌肉注射）诱导的肾上腺皮质反应与给予二十四肽促皮质素后的反应相似。因此，长效二十四肽促皮质素可能是一种替代非吸附性二十四肽促皮质素产品的选择。
